Stocks
By market cap · 24 stocks
- 1
Acadia PharmaceuticalsACADNUPLAZID and DAYBUE neuroscience medicines$4.98B−2.05% - 2
Denali TherapeuticsDNLIDeveloper of blood-brain-barrier-crossing medicines$3.81B−2.76% - 3
ProthenaPRTAPartnered protein-dysregulation pipeline developer$488.5M+2.64% - 4
Inhibikase TherapeuticsIKTPAH-focused kinase drug developer$318.2M−2.23% - 5
Vanda PharmaceuticalsVNDAFanapt and HETLIOZ specialty biopharma$318.1M−2.76% - 6
Anavex Life SciencesAVXLDeveloper of oral therapies for brain disorders$277.1M−4.63% - 7
AC ImmuneACIUDeveloper of neurodegeneration therapies and diagnostics$269.7M−1.66% - 8
AlectorALECABC-enabled neurodegeneration drug developer$259.8M−2.51% - 9
Minerva NeurosciencesNERVSchizophrenia drug developer centered on roluperidone$225.5M−6.04% - 10
Voyager TherapeuticsVYGRTRACER-enabled neurogenetic medicines developer$213.9M+2.31% - 11
Acumen PharmaceuticalsABOSDeveloper of an oligomer-targeting Alzheimer’s antibody$210.9M−3.80% - 12
Alpha CognitionACOGZUNVEYL maker for Alzheimer’s care$142.3M−6.37% - 13
Cognition TherapeuticsCGTXZervimesine developer for Lewy body dementia psychosis$91.3M−3.77% - 14
Annovis BioANVSDeveloper of buntanetap for neurodegenerative disease$73.2M−4.97% - 15
Filana TherapeuticsFLNADeveloper of simufilam for TSC-related epilepsy$44.9M+0.57% - 16
LeonaBioLONADeveloper of breast cancer and ALS therapies$31.6M+1.39% - 17
TAO SynergiesTAOXBittensor TAO treasury and staking vehicle$29.1M−9.46% - 18
CervoMedCRVODeveloper of neflamapimod for brain disorders$24.1M−1.52% - 19
ProMIS NeurosciencesPMNEpiSelect antibody developer for neurodegenerative diseases$18.0M−0.79% - 20
Cyclerion TherapeuticsCYCNSuspended depression system and sGC licensing portfolio$17.7M−6.02% - 21
Greenland MinesGRMLSkaergaard mineral explorer with an ALS biotech program$14.7M−7.03% - 22
Alzamend NeuroALZNAL001 and ALZN002 neuroscience drug developer$6.3M+2.10% - 23
Artelo BiosciencesARTLClinical developer of lipid-signaling drug candidates$2.3M+0.24% - 24
Jupiter NeurosciencesJUNSJOTROL-based CNS drug developer and Nugevia supplement seller$2.0M−15.03%